HTG Molecular Diagnostics Inc (NASDAQ:HTGM) gapped down before the market opened on Thursday . The stock had previously closed at $4.04, but opened at $3.50. HTG Molecular Diagnostics shares last traded at $2.86, with a volume of 2159500 shares changing hands.

A number of research firms have commented on HTGM. Canaccord Genuity raised their price target on HTG Molecular Diagnostics to $5.00 in a report on Friday, January 5th. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the company a “buy” rating in a report on Friday, January 5th. Zacks Investment Research lowered HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Finally, ValuEngine upgraded HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $5.25.

The firm has a market capitalization of $38.92 and a PE ratio of -1.33.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Tuesday, November 7th. The medical research company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.03. equities analysts expect that HTG Molecular Diagnostics Inc will post -1.92 EPS for the current year.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA grew its position in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 416,608 shares of the medical research company’s stock after purchasing an additional 345,798 shares during the period. Granahan Investment Management Inc. MA owned approximately 3.33% of HTG Molecular Diagnostics worth $708,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 15.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “HTG Molecular Diagnostics (HTGM) Shares Gap Down to $3.50” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/htg-molecular-diagnostics-htgm-shares-gap-down-to-3-50/1812761.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.